Research

Our Lady of the Lake Children’s Health is an academic teaching hospital, which means our patients have access to the best of the best when it comes to research and evidence-based practice initiatives. Our research team manages several research endeavors, including clinical trials, quality and safety initiatives, as well as projects that improve patient care.

Current Open Clinical Trials at Our Lady of the Lake Children’s Health

 

BLOOD DISORDERS

Title: GBT HOPE. Study to Evaluate the Effect of GBT440 Administered Orally to Patients With Sickle Cell Disease

Purpose: The purpose is to assess the efficacy of GBT440 in adolescents and adults with sickle cell disease as measured by improvement in anemia.

Principle Investigator: Dr. J. Ryan Shows

Contact: For more information contact Allie Piehet, BS at (225) 215-5909

Open to Enrollment

 

GASTROENTEROLOGY

Title:  MODIFYIII. Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI)

Purpose: The purpose of this study is to determine the safety and effectiveness of the monoclonal antibody bezlotoxumab in children ages 1 to 17 who have a Clostridium difficile infection.

Principal Investigator: Dr. Michael Bolton

Contact: For more information, contact Katie Vance, Ph.D. at (225) 765-4365

Open to enrollment

 

INFECTIOUS DISEASES

Title: MK-7625A-034. MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI)

Purpose: This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) compared with that of meropenem in pediatric participants with cUTI, including pyelonephritis.

Principal Investigator: Dr. Michael Bolton

Contact: For more information, contact Katie Vance, Ph.D. at (225) 765-4365

Open to enrollment


Title: A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections

Purpose: The purpose of this research study is to determine how the body handles a single intravenous dose of imipenem (IMI), cilastatin (CIL), and relebactam (REL) in patients ranging in age from birth up to 17 years old.

Principal Investigator: Dr. Michael Bolton

Contact: For more information, contact Katie Vance, Ph.D. at (225) 765-4365

Open to Enrollment


Title: A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old

Purpose: The purpose of this research study is to test a single intravenous or oral dose of tedizolid phosphate for tolerability and safety in patients ages 2 to <12 years old.

Principal Investigator: Dr. Michael Bolton

Contact: For more information, contact Katie Vance, Ph.D. at (225) 765-4365

Open to Enrollment